Want to see RBGLY full AI Analyst Report?
Top Page
Reckitt Benckiser Group
(OTC:RBGLY)
Select Model
Select Model
Rating:62Neutral
Price Target:
$13.50
â–¼(-14.12% Downside)
Action:Downgraded
Date:03/10/26
The score is held back mainly by weak technical momentum (well below key moving averages with bearish MACD). Fundamentals are steady but not clean—recent revenue and cash-flow pressure plus moderate leverage offset solid profitability. Valuation is a key positive (low P/E and ~3% yield), while the latest call supports a cautiously positive outlook via 2026 growth guidance and cost programs, tempered by near-term margin/FCF and leverage headwinds.
Positive Factors
Emerging Markets Growth
Emerging markets delivered strong double-digit like-for-like growth and margin expansion, reflecting durable structural demand, higher online penetration and favorable mix in China and India. This regional outperformance diversifies revenue, supports long-term margin resilience and reduces reliance on mature markets.
Negative Factors
Rising Leverage
Management expects leverage to increase materially toward ~2.5x in the near term, on top of historically meaningful debt balances. Higher leverage reduces financial flexibility, increases refinancing and interest-rate exposure, and limits the company's ability to invest or absorb shocks if revenue or cash flow weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Emerging Markets Growth
Emerging markets delivered strong double-digit like-for-like growth and margin expansion, reflecting durable structural demand, higher online penetration and favorable mix in China and India. This regional outperformance diversifies revenue, supports long-term margin resilience and reduces reliance on mature markets.
Read all positive factors
Reckitt Benckiser Group (RBGLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.53B
Dividend Yield3.33%
Average Volume (3M)20.41K
Price to Earnings (P/E)12.1
Beta (1Y)0.10
Revenue Growth3.44%
EPS Growth141.37%
CountryUS
Employees38,100
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.96
Shares Outstanding3,175,275,000
10 Day Avg. Volume0
30 Day Avg. Volume20,409
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.08
Price to Sales (P/S)2.83
P/FCF Ratio22.79
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda7.60
Forecast
1Y Price Target
$14.60Price Target Upside-7.12% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)$17.02B
Reckitt Benckiser Group Business Overview & Revenue Model
Company Description
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsi...
How the Company Makes Money
Reckitt primarily makes money by selling branded consumer packaged goods (CPG) to customers worldwide. Revenue is generated through (1) Consumer Health: sales of over-the-counter health, wellness, and self-care products (e.g., analgesics, cold/flu...
Reckitt Benckiser Group Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
63
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.89B | 14.17B | 14.61B | 14.45B | 13.23B |
| Gross Profit | 8.44B | 8.60B | 8.76B | 8.36B | 7.69B |
| EBITDA | 4.61B | 2.96B | 3.19B | 3.65B | 3.02B |
| Net Income | 3.11B | 1.43B | 1.64B | 2.33B | -32.00M |
Balance Sheet | |||||
| Total Assets | 25.02B | 25.30B | 27.14B | 28.74B | 26.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 760.00M | 1.39B | 1.16B | 1.26B |
| Total Debt | 8.42B | 8.66B | 8.54B | 8.88B | 9.56B |
| Total Liabilities | 17.26B | 18.58B | 18.67B | 19.26B | 19.49B |
| Stockholders Equity | 7.73B | 6.70B | 8.45B | 9.44B | 7.40B |
Cash Flow | |||||
| Free Cash Flow | 1.72B | 2.22B | 2.19B | 1.95B | 1.32B |
| Operating Cash Flow | 2.25B | 2.68B | 2.64B | 2.40B | 1.70B |
| Investing Cash Flow | 1.17B | -396.00M | -466.00M | -139.00M | 239.00M |
| Financing Cash Flow | -2.38B | -2.71B | -1.81B | -2.38B | -2.29B |
Reckitt Benckiser Group Technical Analysis
Positive
15.72
Price Trends
12.63
Positive
13.50
Negative
14.57
Negative
Market Momentum
0.29
Negative
60.72
Neutral
53.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBGLY, the sentiment is Positive. The current price of 15.72 is above the 20-day moving average (MA) of 12.90, above the 50-day MA of 12.63, and above the 200-day MA of 14.57, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 60.72 is Neutral, neither overbought nor oversold. The STOCH value of 53.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RBGLY.
Reckitt Benckiser Group Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $341.95B | 21.12 | 31.32% | 2.92% | 3.33% | 8.06% | |
69 Neutral | $131.39B | 28.56 | 26.01% | 3.74% | -13.78% | 11.80% | |
65 Neutral | $22.67B | 31.73 | 17.45% | 1.38% | 2.22% | 29.40% | |
64 Neutral | $72.83B | 35.67 | 475.13% | 2.67% | 4.26% | -27.12% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $42.53B | 12.06 | 45.27% | 3.33% | 3.44% | 141.37% | |
61 Neutral | $36.49B | 17.70 | 143.64% | 5.03% | -16.17% | -13.40% |
* Consumer Defensive Sector Average
RBGLY
Reckitt Benckiser Group
13.46
0.32
2.44%
CHD
Church & Dwight
96.36
0.55
0.57%
CL
Colgate-Palmolive
92.24
5.58
6.44%
KMB
Kimberly Clark
112.41
-9.10
-7.49%
PG
Procter & Gamble
147.04
-2.42
-1.62%
UL
Unilever
61.72
-1.41
-2.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.